Form 4: Heron Therapeutics EVP Ira Duarte Reports Stock Transactions
SEC Form 4 Filing
EVP and Chief Financial Officer of Heron Therapeutics, Ira Duarte, reports the acquisition of 12,500 shares of common stock through the vesting of restricted stock units.
Summary
- Ira Duarte, the EVP and Chief Financial Officer of Heron Therapeutics, reported a transaction involving the company's stock on June 16, 2024.
- The transaction involved the acquisition of 12,500 shares of common stock through the vesting of restricted stock units.
- Following the reported transaction, Duarte directly owns 100,252 shares of Heron Therapeutics common stock.
- Duarte also owns 37,500 restricted stock units.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock transactions by an executive.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- Provides transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 06/16/2024 | Date of stock transaction and vesting of restricted stock units. |
| 06/17/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.